Business
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Aff
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"Helus Pharma","displaySize":"","headline":null,"caption":"Helus Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":158,"url":"https://media.zenfs.com/en/globenewswire.com/686bbe5b91123e89e8409b06693f4c30"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qexFcYmxzx_9Vfd0WMfkJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMQ--/https://media.zenfs.com/en/globenewswire.com/686bbe5b91123e89e8409b06693f4c30","width":300,"height":158}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement","length":179,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":179,"olType":false},{"type":"text","content":"NEW YORK and TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the appointment of Dr. Ken Kramer, PhD as Senior Vice President, Medical Affairs, effective immediately.","length":348,"tagName":"p"},{"type":"text","content":"Dr. Kramer joins Helus with more than two decades of experience leading medical affairs strategy across neuroscience programs, including global launch readiness, evidence generation, and engagement with key opinion leaders. Most recently, he served as Vice President and Head of Medical Neuroscience at Bristol Myers Squibb, where he led an integrated medical strategy team to successfully launch the first new treatment for schizophrenia in over seven decades.","length":461,"tagName":"p"},{"type":"text","content":"“Strong medical leadership is vital to how we connect with and serve the scientific and clinical communities,” said Michael Cola, Chief Executive Officer of Helus Pharma. “Dr. Kramer brings both deep experience and an execution mindset to help us scale medical capabilities and advance our pipeline. His leadership will be instrumental in translating strong science into meaningful engagement with patients, providers, and payors.”","length":431,"tagName":"p"},{"type":"text","content":"At Karuna Therapeutics, as VP and Head of Medical Affairs, Dr Kramer built and expanded medical capabilities during a pe...